Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

BDRX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 30, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Biodexa Pharmaceuticals PLC (BDRX)

Based on 7 analysts giving stock ratings to Biodexa Pharmaceuticals PLC in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
43
Buy
43
Hold
14
Sell
0
Strong Sell
0
Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC. Stock Analysis BDRX

United States Health Care Nano Cap Report:
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 11 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Read More

Biodexa Pharmaceuticals PLC (BDRX) Chart

Key Statistics of Biodexa Pharmaceuticals PLC (BDRX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$2.63$2.77

Today's Open

$2.63

Volume

26.77K

P/E Ratio (TTM)

-

52 Week Range

$2.45$66.50

Market Cap

1.40M

Avg. Volume

23.17K

Dividend Yield

-

Financial Metrics & Statements of Biodexa Pharmaceuticals PLC (BDRX)

FAQ's for Biodexa Pharmaceuticals PLC (BDRX)

  • According to Musaffa’s Shariah screening methodology, Biodexa Pharmaceuticals PLC (BDRX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Biodexa Pharmaceuticals PLC using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Biodexa Pharmaceuticals PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Biodexa Pharmaceuticals PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Biodexa Pharmaceuticals PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Biodexa Pharmaceuticals PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.